BLUE: Rasio rega marang pendapatan bluebird bio Inc.
bluebird bio, Inc. (BLUE) leads in blood gene therapy, ensuring high margins and stable cash flow. The price-to-sales ratio demonstrates valuation dynamics, where 0.50 reflects the latest metric value. Growth depends on Lyfgenia sales and insurance coverage, while the strategy shifts toward the industrial scaling of approved vectors and the implementation of commercial protocols.
Rincian analitis perusahaan bluebirdbio.com (BLUE)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- statistik nilai buku emiten:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi bluebird bio, Inc.|BLUE - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal bluebirdbio.com|BLUE - Utang perusahaan|Rasio utang marang nilai buku bluebird bio, Inc|BLUE - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan bluebird bio|Koefisien jangkoan perantara bluebirdbio.com
- data bathi resik lan rasio valuasi:
BLUE - Bathi resik|Bathi sing dikarepake bluebird bio, Inc.|BLUE - Rasio rega marang bathi|Rega marang bathi mangsa ngarep bluebird bio, Inc.|BLUE - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA bluebird bio, Inc|BLUE - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan bluebird bio|BLUE - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan bluebirdbio.com|BLUE - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep bluebird bio, Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:bluebird bio (BLUE)
To select assets with a high margin of safety, analyzing the price-to-sales ratio is critical, as it allows for an assessment of business overvaluation relative to generated cash flow. This price-to-sales multiple reflects the monetization efficiency of bluebird bio, Inc. (BLUE) gene therapies, helping investors correlate the company's valuation with revenues from rare disease treatments and partnership payments.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc - Multiplikator P/S|OCGN - Multiplikator P/S|PACB: Multiplikator P/S|BNTC - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Design Therapeutics, Inc.|RCKT: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Korro Bio, Inc. KRRO|EDIT: Rasio kapitalisasi marang pendapatan|SLN - Rasio rega marang pendapatan|Multiplikator rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Kapitalisasi marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator P/S|Rasio rega marang pendapatan Nautilus Bio|Rega marang dodolan Metagenomi Therapeutics MGX|Rasio rega marang pendapatan Precision BioSciences (DTIL)|GBIO - Rega marang dodolan|Multiplikator P/S BOLD (Boundless Bio, Inc)|XCUR - Kapitalisasi marang pendapatan|IMNN - Rasio rega marang pendapatan|Rega marang dodolan Phio Pharmaceuticals Corp|MBIO: Multiplikator P/S|TransCode (RNAZ) - Multiplikator P/S|BNGO (Bionano) - Multiplikator P/S|Rega marang dodolan Applied DNA Sciences, Inc. APDN|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
